Best of cannabinoid science this week...
In humans with PTSD, low doses of THC helped with fear memory processes & extinction learning, both acutely & one week after administration
Dose-dependent effect of acute THC on extinction memory recall and fear renewal: a randomized, double-blind, placebo-controlled study
In people with hand pain, a survey found that the ones using cannabinoids found a similar painkilling effect to prescription medications
Prevalence and Effect of Cannabinoids in Pain Management for Hand Pathologies
In states that legalized medical or recreational cannabis, they had higher levels of physical activity & exercise
Association between cannabis use and physical activity in the United States based on legalization and health status
Finally, someone did a straightforward clinical study of how phytocannabinoids alter the endocannabinoid levels in your blood
Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers
"CBD-led increases in AEA (1.6-fold), OEA and PEA (1.4-fold) were observed following a single 800 mg (pcorr<0.05) but not 600 mg dosage. Declining AEA was observed with Δ9-THC at 10 mg (-1.3-fold) and 20 mg (-1.4-fold) but restored to baseline levels by 160 min. CBD+Δ9-THC yielded the highest increases in AEA (2.1-fold), OEA (1.9-fold) and PEA (1.8-fold) without reaching a maximal response.”
In a related study, in 300 people randomly assigned to products dominant in THC, CBD or both, this research measured the effects on their endocannabinoid levels
The Interplay of Exogenous Cannabinoid Use on Anandamide and 2-Arachidonoylglycerol in Anxiety: Results from a Quasi-Experimental Ad Libitum Study
“The findings suggest that AEA levels do not change differently based on 4 weeks of cannabis use or by cannabinoid content, as AEA similarly increased across all conditions from study weeks 2 to 4. In contrast, AEA decreased at an acute administration session with product conditions containing any THC having greater AEA levels on average than the non-use condition. With regard to 2-AG, its levels appeared to primarily be affected by THC-dominant use, both acutely and over 4 weeks, when controlling for baseline cannabis use and examining study product use frequency among use conditions.”
And in another related study, this team measured how cannabis altered immune functions & had anti-inflammatory effects across a range of cell types in the brain
DELTA-9-TETRAHYDROCANNABINOL MODULATES IMMUNOGENOMIC FUNCTION AT SINGLE CELL RESOLUTION USING 10X MULTIOME PROFILING: IN VIVO HUMAN SUBJECT STUDY
In obese people, 8 weeks of 125 mg of oleoylethanolamide (the “anti-hunger” endocannabinoid-like molecule) lowered triglyceride levels
The effect of Oleoylethanolamide supplementation on lipid profile, fasting blood sugar and dietary habits in obese people: a randomized double-blind placebo-control trial
In people exposed to UVA light on their buttocks for two weeks (heroes of science, all of them), two daily topical applications of nano-CBD reduced their redness levels, lowered hyperplasia (abnormally high cell production, a sign of cancer) & protected the skin’s mitochondria (powerhouse of the cell)
Topical Nanoencapsulated Cannabidiol Cream as an Innovative Strategy Combatting Ultraviolet A-Induced Nuclear and Mitochondrial DNA Injury: A Pilot Randomized Clinical Study
A review of the endocannabinoid system as a system of homeostasis (balance)
The Endocannabinoid System Signaling, a Precursor to Homeostasis: A Scoping Review
And a thorough review of cannabis as a food & medicine
Cannabis for medicine and food: A benefit vs risk critical appraisal
For fibromyalgia, a review of 19 publications found improvements to pain, sleep habits & quality of life with no serious adverse events
Effectiveness and safety of cannabis-based products for medical use in patients with fibromyalgia syndrome: A systematic review
For insomnia, a review of six articles found some studies linking medical cannabis with an improvement in sleep quality
The Modulating Role of Cannabis in Insomnia: A Review of the Literature
For migraines, a review of the neural immune cells & the effects of the cannabinoids
Interplay between cannabinoids and the neuroimmune system in migraine
For anxiety, a review of CBD trials that are recent or ongoing
Review of the current ongoing clinical trials exploring the possible anti-anxiety effects of cannabidiol
For neurological disorders, a review of using the cannabinoids
Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders
For depression, a review on targeting the endocannabinoid system
An overview of major depression disorder: The endocannabinoid system as a potential target for therapy
For inflammatory bowel disease, a review on using cannabis
The Potential of Cannabis in Managing Inflammatory Bowel Disease and Its Future Perspective
In a mouse model of Alzheimer's disease, CBD lowered cognitive decline via glycine receptors in the hippocampus
Cannabidiol ameliorates cognitive decline in 5×FAD mouse model of Alzheimer’s disease through potentiating the function of extrasynaptic glycine receptors
In a rat model of osteoarthritis, the lesser-known cannabinoid cannabiorcol lowered inflammation & osteoarthritis symptoms
Cannabiorcol as a novel inhibitor of the p38/MSK-1/NF-κB signaling pathway, reducing matrix metalloproteinases in osteoarthritis
In honey bees, the anandamide produced by their gut bacteria promoted reward learning
Gut symbiont-derived anandamide promotes reward learning in honeybees by activating the endocannabinoid pathway
Comments